Evidence map›Paper›PMID 34838994›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2022

Lung function improves after delayed treatment with CNP-miR146a following acute lung injury.

Stephen M Niemiec, Sarah A Hilton, Alison Wallbank, Amanda E Louiselle, Hanan Elajaili, Junyi Hu, Sushant Singh, Sudipta Seal, Eva Nozik, Bradford Smith and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Modulatory effects of CeOParticle and fibre toxicology · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Stephen M NiemiecLaboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
Sarah A HiltonLaboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
Alison WallbankDepartment of Bioengineering, University of Colorado Denver | Anschutz Medical Campus, Aurora, CO, USA.
Amanda E LouiselleLaboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
Hanan ElajailiCardiovascular Pulmonary Research Laboratories and Pediatric Critical Care Medicine, Department of Pediatrics, University of Colorado, Aurora, CO, USA.
Junyi HuLaboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
Sushant SinghAmity Institute of Biotechnology, Amity University Chhattisgarh, Raipur, Chhattisgarh, India; Department of Material Science and Engineering, Advanced Materials Processing and Analysis Center, Nanoscience Technology Center, University of Central Florida, Orlando, FL, USA.
Sudipta SealDepartment of Material Science and Engineering, Advanced Materials Processing and Analysis Center, Nanoscience Technology Center, University of Central Florida, Orlando, FL, USA; College of Medicine, UCF Prosthetics Cluster, University of Central Florida, Orlando, FL, USA.
Eva NozikCardiovascular Pulmonary Research Laboratories and Pediatric Critical Care Medicine, Department of Pediatrics, University of Colorado, Aurora, CO, USA.
Bradford SmithDepartment of Bioengineering, University of Colorado Denver | Anschutz Medical Campus, Aurora, CO, USA.
Carlos ZgheibLaboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
Kenneth W LiechtyLaboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, CO, USA. Electronic address: ken.liechty@cuanschutz.edu.
University of Colorado Denver · USChildren's Hospital Colorado · USUniversity of Central Florida · US

Funding

SOD3 regulation of redox sensitive signaling in pulmonary vascular diseasesR35HL139726 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI NOZIK, EVA S. · 2018 to 2024
$4.1M
NHLBI NIH HHS R35 HL139726
6 · The paper itself

Abstract

Acute respiratory distress syndrome (ARDS) is a highly morbid pulmonary disease characterized by hypoxic respiratory failure. Its pathogenesis is characterized by unrestrained oxidative stress and inflammation, with long-term sequelae of pulmonary fibrosis and diminished lung function. Unfortunately, prior therapeutic ARDS trials have failed and therapy is limited to supportive measures. Free radical scavenging cerium oxide nanoparticles (CNP) conjugated to the anti-inflammatory microRNA-146a (miR146a), termed CNP-miR146a, have been shown to prevent acute lung injury in a pre-clinical model. In this study, we evaluated the potential of delayed treatment with CNP-miR146a at three or seven days after injury to rescue the lung from acute injury. We found that intratracheal CNP-miR146a administered three days after injury lowers pulmonary leukocyte infiltration, reduce inflammation and oxidative stress, lower pro-fibrotic gene expression and collagen deposition in the lung, and ultimately improve pulmonary function.

Indexed as

Acute Lung InjuryLung InjuryNanoparticlesCeriumHumansLungTime-to-Treatmentceric oxideCeriumAcute lung injuryAcute respiratory distress syndromeCerium oxide nanoparticles (CNP)microRNA-146a (miR146a)Pulmonary fibrosis

Identifiers

PMID34838994
PMCPMC8616767
OpenAlexW3217581925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.